home / stock / bpmc / bpmc quote
$98.22 Last:
2.22% Change Percent:
$96.9 Open:
$98.22 Previous Close:
$99.17 High:
$94.03 Low:
454,432 Volume:
02/26/2021 04:55:21 pm Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
Stock Date | Open Price | Close Price | High | Low | Volume |
---|---|---|---|---|---|
2021-02-26 | 96.9 | 98.22 | 99.17 | 94.03 | 454,432 |
2021-02-25 | 97.74 | 96.09 | 98.7105 | 94.83 | 341,402 |
2021-02-24 | 97.17 | 97.79 | 98.96 | 94.95 | 303,002 |
2021-02-23 | 96.35 | 97.45 | 99.92 | 94.04 | 441,602 |
2021-02-22 | 99.75 | 97.96 | 100 | 96.85 | 351,193 |
2021-02-19 | 96.81 | 100.31 | 101.52 | 96.61 | 481,598 |
2021-02-18 | 99.4 | 96.74 | 99.4 | 96 | 338,822 |
2021-02-17 | 90.47 | 100.25 | 102.67 | 90.41 | 786,210 |
2021-02-16 | 97.06 | 93.2 | 97.8815 | 93.05 | 423,897 |
2021-02-15 | 100.45 | 96.97 | 100.6 | 96.225 | 287,512 |
2021-02-12 | 100.45 | 96.97 | 100.6 | 96.225 | 285,618 |
2021-02-11 | 100.58 | 100.31 | 102.0399 | 98.18 | 397,131 |
2021-02-10 | 103.01 | 99.38 | 103.745 | 98.23 | 424,684 |
2021-02-09 | 105.28 | 103.19 | 106.94 | 102.89 | 295,302 |
2021-02-08 | 103 | 105.45 | 107.1 | 101.0601 | 484,146 |
2021-02-05 | 99.59 | 102 | 102.49 | 98.695 | 335,764 |
2021-02-04 | 96.15 | 98.97 | 98.98 | 95.49 | 215,543 |
2021-02-03 | 100.19 | 96.35 | 100.3 | 95.55 | 399,750 |
2021-02-02 | 100.29 | 100.35 | 103.24 | 99.59 | 467,707 |
2021-02-01 | 97.54 | 98.57 | 98.8 | 95 | 529,815 |
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
News, Short Squeeze, Breakout and More Instantly...
Blueprint Medicines Reports Fourth Quarter and Full Year 2020 Financial Results -- Supplemental NDA accepted by FDA for AYVAKIT™ (avapritinib) for advanced systemic mastocytosis -- -- Type II variation MAA submitted to EMA for AYVAKYT® (avapritinib) for advanced ...
Blueprint Medicines to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 17, 2021 PR Newswire CAMBRIDGE, Mass. , Feb. 10, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused...
Blueprint Medicines Announces R&D Leadership Transitions Blueprint Medicines Announces R&D Leadership Transitions -- Becker Hewes, M.D., promoted to Chief Medical Officer -- -- Andy Boral, M.D., Ph.D., to transition from Chief Medical Officer to Executive Vice Pr...